Uniunea Europeană - daneză - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

sintetica gmbh - droperidol - injektionsvæske, opløsning - 0,5 mg/ml

Uniunea Europeană - daneză - EMA (European Medicines Agency)

sanofi b.v. - vandetanib - thyroid neoplasms - antineoplastiske og immunomodulerende midler - caprelsa er indiceret til behandling af aggressiv og symptomatisk medulær thyreoideacancer (mtc) hos patienter med uopløselig lokalt avanceret eller metastatisk sygdom. caprelsa er indiceret hos voksne, børn og unge i alderen 5 år og ældre. for patienter, hos hvem re-arrangeret-under-transfektion(ret) mutation ikke kendes, eller er negativ, og en eventuel lavere ydelse skal tages i betragtning, inden individuel behandling beslutning.

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

ever neuro pharma gmbh - apomorphinhydrochlorid hemihydrat - infusionsvæske, opløsning - 5 mg/ml

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

ever neuro pharma gmbh - apomorphinhydrochlorid hemihydrat - injektionsvæske, opløsning i cylinderampul - 10 mg/ml

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - tramadolhydrochlorid - kapsler, hårde - 50 mg

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - tramadolhydrochlorid - suppositorier - 100 mg

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

medartuum ab - apomorphinhydrochlorid hemihydrat - infusionsvæske, opløsning - 5 mg/ml

Danemarca - daneză - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - apomorphinhydrochlorid hemihydrat - infusionsvæske, opløsning - 5 mg/ml

Uniunea Europeană - daneză - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, lunge - antihypertensive midler til pulmonal arteriel hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har været vist i en pah befolkningen, herunder aetiologies af idiopatisk eller arvelige pah eller pah, der er forbundet med bindevævssygdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.